Nexalin Technology, Inc. NXL 深 滬
等待開盤 10-21 09:30:00 美东时间
1.68
+0.160
+10.53%
華盛通- 最 高1.68
- 今 開1.49
- 成交量 116.96万股
- 最 低 1.4508
- 昨 收 1.52
- 總市值 2885.89万
- 52周最高 4.4899
- 市盈率 靜 --
- 換手率 6.81%
- 52周最低 0.702
- 委 比 -56.04%
- 總股本 1717.79万
- 歷史最高 4.4899
- 量 比 1.45
- 振 幅 15.08%
- 歷史最低 0.2528
- 每 手 1
- 風險率 1.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nexalin Technology Amends Equity Distribution Agreement
An announcement from Nexalin Technology, Inc. ( ($NXL) ) is now available. On O...
10-16 05:17
Nuix Ltd. Issues 50,000 Performance Rights in Employee Incentive Scheme
Nuix Ltd. ( ($AU:NXL) ) has provided an update. Nuix Ltd. announced the issuanc...
10-13 12:17
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
Nexalin Technology, Inc., a leader in Deep Intracranial Frequency Stimulation (DIFS™), will participate in the 2025 Maxim Growth Summit on October 22 at The Hard Rock Hotel NYC. The event will allow attendees to engage with Nexalin’s management and learn about its proprietary, non-invasive neurostimulation, a drug-free, clinically proven treatment for global mental health issues. Nexalin’s devices, designed to penetrate deep brain structures link...
10-10 12:00
3 Penny Stocks to Watch Now, 10/9/25
Nuburu, Nexalin Technology, and Connexa Sports Technologies are the 3Penn...
10-09 23:51
Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?
Nexalin stock surged as new clinical data showed its Gen-2 device improved cognition and brain connectivity in mild Alzheimer's patients without safety concerns.
10-09 02:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
<p>Nexalin’s 40-Hz DIFS™ technology demonstrates significant cognitive improvements and enhanced brain connectivity in Alzheimer’s patients, as shown in a peer-reviewed clinical trial published in Radiology. The study highlights statistically significant gains in MMSE and MoCA scores, improved hippocampal-cortical connectivity, and safety. With global AD market potential, Nexalin aims to expand its non-invasive neurostimulation solutions for neur...
10-08 12:30
NexLiving Expands Portfolio with Ottawa Townhome Acquisition
NexLiving Communities Inc ( ($TSE:NXLV) ) just unveiled an update. NexLiving Co...
09-26 01:08
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
Nexalin Technology, Inc. announced the issuance of U.S. Design Patent No. D1,092,758 for its HALO™ Clarity neuromodulation device, providing 15 years of design protection. The device delivers non-invasive Deep Intracranial Frequency Stimulation (DIFS™) to treat mental health and neurological conditions like Alzheimer’s, anxiety, and PTSD. Designed for at-home use with remote clinician oversight, HALO™ Clarity aims to improve accessibility, compli...
09-25 12:30
